Preventing and limiting minimal residual disease following targeted cancer therapy

Description of the granted funding

While targeted therapy has transformed the treatment of cancer, the long-term efficacy of these strategies is severely compromized by drug resistance. In the center stage of this process is the ability of some cancer cells to adapt to drug treatment and lay dormant for long period of time. Clinically this phenomenon is observed as minimal residual disease in most patients treated with targeted therapies. The aim of this reserach is to investigate the means cancer cells use to adapt to drug treatment and understand how residual tumor cells modulate the immune system during residual disease. The ultimate goal is to identify vulnerabilities in residual cancer cells, or in the mechanisms that allow the establishment of residual disease, in order to develop combination treatments that will prevent residual disease. This could significantly improve the long-term efficacy of cancer treatments.
Show more

Starting year

2021

End year

2026

Granted funding

Kari Kurppa Orcid -palvelun logo
447 650 €

Related funding decisions

361970
Research costs of Academy Research Fellows(2024)
199 465 €
346656
Research costs of Academy Research Fellows(2021)
300 000 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

338466

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer